Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer.
| Autor: | Cramer-van der Welle CM; Santeon Hospital Group, Utrecht, The Netherlands., Schramel FMNH; Department of Pulmonary Diseases, St Antonius Hospital, Utrecht/Nieuwegein, The Netherlands., van Leeuwen AS; Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands., Groen HJM; Department of Pulmonary Diseases, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands., van de Garde EMW; Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.; Department of Clinical Pharmacy, St. Antonius Hospital, Utrecht/Nieuwegein, The Netherlands. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | European journal of cancer care [Eur J Cancer Care (Engl)] 2020 Sep; Vol. 29 (5), pp. e13250. Date of Electronic Publication: 2020 May 14. |
| DOI: | 10.1111/ecc.13250 |
| Abstrakt: | Objective: Clinical outcome data on patients with extensive disease small cell lung cancer (ED SCLC) treated in routine practice is limited. The aim of this retrospective study is to present data on treatment patterns and survival in an unselected patient population with ED SCLC. Methods: All patients diagnosed with ED SCLC between 2008 and 2014 in six Dutch large teaching hospitals (Santeon network) were included. We collected data on patient characteristics, systemic treatments, overall survival (OS), dose reductions (<80% of initial dose) and early discontinuation (<4 cycles). Results: From 792 diagnosed patients, 568 (72%) started with first-line treatment. Of these patients, 41% received second-line treatment. Only 68 patients received third-line treatment. For all treated patients, the mean age was 66 years. The majority (72%) had a performance status (ECOG) of 0 or 1 at diagnosis. Median OS of treated patients was 7.4 months. Of all patients with first-line treatment, 26% received <4 cycles and dose reductions were observed in 29%. Conclusion: After first-line systemic treatment in ED SCLC the fraction of patients receiving subsequent lines of treatment is rapidly decreasing. This information is necessary as background for evaluation of the added value of future drugs under study for ED SCLC. (© 2020 The Authors. European Journal of Cancer Care published by John Wiley & Sons Ltd.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|